Introduction

Despite the great advances in both primary and secondary prevention, cardiovascular diseases still represent the main cause of death in Western countries (1). Metabolic derangements such as diabetes, obesity, and dyslipidemia are critical factors that directly promote the development of coronary artery disease, stroke, and heart failure and dramatically affect the prognosis of subjects affected by cardiovascular diseases (1).

These metabolic abnormalities are frequently associated in the context of metabolic syndrome. Metabolic syndrome has a significant impact on the general population with a prevalence ranging from 25% to 35% (1,2). Metabolic syndrome and diabetes promote atherosclerotic plaque formation and rupture; they promote changes in cardiac geometry and functional abnormalities such as cardiac hypertrophy and diastolic dysfunction; they increase the cardiac susceptibility to ischemia and maladaptive remodeling; they are independently associated with the incidence of heart failure (1,2). At the molecular level, metabolic syndrome and diabetes induce oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis (3). These abnormalities are responsible for endothelial dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis and dysfunction associated with metabolic abnormalities.

Abstract: Diabetes, obesity, and dyslipidemia are main risk factors that promote the development of cardiovascular diseases. These metabolic abnormalities are frequently found to be associated together in a highly morbid clinical condition called metabolic syndrome. Metabolic derangements promote endothelial dysfunction, atherosclerotic plaque formation and rupture, cardiac remodeling and dysfunction. This evidence strongly encourages the elucidation of the mechanisms through which obesity, diabetes, and metabolic syndrome induce cellular abnormalities and dysfunction in order to discover new therapeutic targets and strategies for their prevention and treatment. Numerous studies employing both dietary and genetic animal models of obesity and diabetes have demonstrated that autophagy, an intracellular system for protein degradation, is impaired in the heart under these conditions. This suggests that autophagy reactivation may represent a future potential therapeutic intervention to reduce cardiac maladaptive alterations in patients with metabolic derangements. In fact, autophagy is a critical mechanism to preserve cellular homeostasis and survival. In addition, the physiological activation of autophagy protects the heart during stress, such as acute ischemia, starvation, chronic myocardial infarction, pressure overload, and proteotoxic stress. All these aspects will be discussed in our review article together with the potential ways to reactivate autophagy in the context of obesity, metabolic syndrome, and diabetes.

Keywords: Autophagy; diabetes; metabolic syndrome; obesity; heart

Submitted Apr 21, 2015. Accepted for publication Jul 13, 2015.
doi: 10.3978/j.issn.2223-3652.2015.07.02
View this article at: http://dx.doi.org/10.3978/j.issn.2223-3652.2015.07.02
syndrome and diabetes (3). This evidence strongly indicates that, aside from the battle to improve primary prevention critical for the reduction of metabolic syndrome and diabetes incidence, which unfortunately in many cases is lost, it is crucial to develop new therapeutic strategies aimed at reducing the cellular abnormalities induced by these morbid conditions. However, this can be possible only if we better elucidate the mechanisms through which obesity, dyslipidemia, and hyperglycemia induce cellular abnormalities and dysfunction.

Accumulating lines of evidence indicate that obesity, diabetes, and metabolic syndrome are associated with a significant impairment of autophagy in multiple organs (4-13). Autophagy is an evolutionarily conserved cellular mechanism for degradation of old damaged proteins and organelles through their sequestration by double membrane vesicles called autophagosomes that subsequently deliver their content to lysosomes for final digestion (14). Autophagy is a beneficial mechanism for cellular homeostasis by guaranteeing the normal turnover of mitochondria and protein and by providing new substrates for protein synthesis and energy production (14,15). Autophagy is also involved in the physiological regulation of metabolic processes (4-11,14,15). In both genetic and dietary models of obesity, autophagy is inhibited in the liver thereby promoting ER stress and insulin resistance (4,6). Autophagy defects in pancreatic β-cells contribute to the transition from obesity to diabetes (7,16). Autophagy is also reduced in the mediobasal hypothalamus of obese animals (9). Impairment of hypothalamic autophagy was found to promote increased food intake, to reduce energy expenditure and to exacerbate the progression of obesity and whole-body insulin resistance (9). Autophagy is also impaired in macrophages during obesity, leading to an increased immune response and tissue inflammation (8). Autophagy was also found to be inhibited in the adipose tissue by obesity, although other works conflicted with this finding by demonstrating that autophagy is activated in the adipose tissue in the presence of metabolic abnormalities, where it favors adipogenesis (11). In addition, proteinuria-induced autophagy is impaired in the kidneys of obese animals thereby worsening proximal tubule damage (10).

Multiple studies in recent years have investigated whether obesity, diabetes, and metabolic syndrome affect autophagy in the heart both in unstressed and stressed conditions (12,13,17-32). Although it is still debated whether these conditions affect more the autophagosome formation with respect to the autophagic flux or vice versa (18,19), the most relevant information emerging from the majority of these studies is that cardiac autophagy is inhibited by metabolic derangements (12,13,17,18-29). Autophagy defects are associated with cardiac abnormalities and increased susceptibility to cardiac stress in the presence of obesity and reactivation of autophagy appears to be cardioprotective (12,13,19,23,28). This evidence opens up new scenarios where autophagy reactivation may represent a potential future therapeutic intervention to reduce cardiac abnormalities in patients with metabolic abnormalities.

All these aspects will be discussed in our review article together with the potential ways to reactivate autophagy in the context of obesity, metabolic syndrome, and diabetes.

**The impact of obesity and diabetes on cardiac autophagy**

In recent years, numerous studies have clarified the role of autophagy in the heart (17,33-35). Autophagy is required for the maintenance of cardiac function and structure at baseline (17,33-35). In addition, autophagy is progressively inhibited during aging, and such decline of autophagy is paralleled by the development of aging-induced cardiac abnormalities (17,33-35). Autophagy also plays a critical role in the regulation of cardiomyocyte survival and death during stress (17,33-35). Although high activation of autophagy is detrimental in specific cardiac stress conditions, autophagy is usually an adaptive mechanism regulating the cardiac response to stress. Autophagy is rapidly activated during myocardial ischemia and starvation where it reduces infarct size by limiting the ATP reduction and ER stress and by favoring mitochondrial turnover (13,36). A similar protective effect is observed in response to chronic myocardial infarction and pressure overload, where autophagy offsets cardiac remodeling and dysfunction in response to these stresses (37,38). Autophagy is also a protective mechanism in cardiac diseases caused by the accumulation of misfolded proteins, where autophagy limits ER stress (39). Overall, this evidence strongly indicates that autophagy is a critical protective mechanism during cardiac stress. Therefore, defects of this pro-survival mechanism would affect both cardiac homeostasis and response to stress. This was confirmed by a recent study that demonstrated that autophagy activation is inversely correlated with mortality in patients undergoing cardiac surgery (40).

Obesity, diabetes, and metabolic syndrome are morbid conditions associated with an increased incidence of
Cardiac autophagy is impaired in animals with diet-induced insulin resistance, metabolic syndrome, and type II diabetes. We found that high-fat diet (HFD)-induced obesity and metabolic syndrome impair cardiac autophagy at baseline and after myocardial ischemia, as indicated by a reduced number of autophagosomes with and without lysosomal inhibitors (GFP-LC3 puncta) (13). Autophagy inhibition by obesity increased the susceptibility to myocardial ischemia. Consistent with our results, He et al. showed inhibition of autophagy by HFD, and data from Mentzer’s group also confirmed a reduction in autophagosome number (mCherry-LC3 puncta) in the hearts of mice fed a similar type of HFD (60% of calories from fat), thus indicating reduced autophagosome formation (23,47). Recent studies also showed reduced LC3-II levels and increased p62 accumulation in mice with HFD-induced obesity, again indicating reduced autophagosome formation (18,21,48,49). In these studies autophagy inhibition by HFD was exacerbated by adiponectin deletion, whereas it was rescued by macrophage migration inhibitory factor (MIF) knockout and catalase overexpression. This data was also confirmed in large animals. Ossabaw pigs with metabolic syndrome induced by an atherogenic diet also displayed reduced cardiac autophagy, as indicated by reduced levels of LC3-II and Beclin-1, which paralleled the development of cardiac abnormalities and dysfunction (24). Similarly, hypercholesterolemia in Yucatan pigs fed high cholesterol diet for 4 weeks inhibited LC3-II/I ratio and cardiac tolerance to myocardial ischemia (25).

Interestingly, HFD was also shown to inhibit autophagy by affecting the fusion of autophagosomes with lysosomes. In mice fed with HFD (45% of calories from fat) for 12 weeks and fasted for 6 hours before all the analyses, LC3-II and p62 levels in the heart were found to be increased with respect to controls (22). Interestingly, LC3-II and p62 levels increased after lysosome inhibition in mice fed with control diet, whereas they did not further increase in HFD mice. These results indicate a defect in autophagic flux and confirm the study by Xu et al. demonstrating an impairment of autophagic flux in HFD mice, which can be rescued by Akt2 gene deletion (19). In addition, this evidence corroborates the study by Mellor et al., which for the first time reported an accumulation of LC3-II and p62 in the hearts of mice with type II diabetes induced by high-fructose diet (30).

Of note, two recent studies from Ren’s group showed that under a similar regimen of HFD, cardiac LC3-II levels can be either decreased or increased as a consequence of autophagy inhibition (18,19). We speculate that these works may suggest that HFD affects both autophagosome formation and flux at the same time. Whether a reduction of autophagosome formation or an impairment of flux is the most prominent defect of cardiac autophagy induced by HFD may depend on the duration and type of the diet, the severity of obesity and associated metabolic abnormalities, gender and age, degree of cardiac hypertrophy and dysfunction, mouse strain, circadian factors, and different experimental conditions. Interestingly, chronic flux inhibition may transcriptionally inhibit LC3 (47), thereby suggesting a secondary inhibition of autophagosome formation and, in general, a tight relationship between autophagosome formation and clearance.

Cardiac autophagy is also impaired in mice with type I diabetes. In mice with streptozotocin-induced
type I diabetes and in OVE26 diabetic mice, cardiac autophagosome production, as indicated by LC3-II levels, is significantly decreased with and without lysosome inhibitors (26-28). Autophagic flux was also found to be inhibited in mice with streptozotocin-induced diabetes, through inhibition of SIRT1 and RAB7 (29).

The main mechanism through which autophagy is impaired in the hearts of mice with obesity and diabetes is the activation of mTORC1 signaling, a strong negative regulator of autophagy (13,18,19,21,24,48,50). mTORC1 was found to be activated by HFD and in models of diabetes. We found a deregulated Rheb/TORC1 activation in the hearts of mice fed HFD that is responsible for autophagy suppression (13). AKT2 activation was also found to be activated by HFD and to promote mTOR activation and autophagy inhibition (19). AMPK, a negative regulator of mTOR, is suppressed in the hearts of diabetic mice (13,18,19,21,26-29,48). Of note, inhibition of AMPK was also found to inhibit autophagy in these animals through an increased interaction between Beclin-1 and BCL-2 (28), thereby confirming our previous evidence demonstrating that MST1-dependent Beclin-1-BCL-2 interaction negatively regulates autophagy and cardiomyocyte survival (37). SIRT1, a protein deacetylase known to promote autophagy, was also found to be inhibited by diabetes (24,29). Lipids can affect autophagic flux through a superoxide-dependent impairment of lysosomal acidification (22). Interestingly, Rodriguez-Navarro’s group previously showed that lipotoxicity may also directly affect chaperone-mediated autophagy, an alternative form of protein degradation (51).

**Potential therapeutic efficacy of autophagy reactivation for the treatment of diabetes-induced cardiovascular abnormalities**

Obesity and diabetes are associated with the development of cardiovascular abnormalities (1-3). Recent work consistently demonstrated that cardiac autophagy is inhibited in these two conditions (12,13,17-29). The most intriguing and relevant aspect of this evidence is whether reactivation of autophagy may prevent or reduce the cardiovascular abnormalities induced by metabolic derangements. Recent studies suggest that this may be true. Reactivation of autophagy in mice with type I and II diabetes improved cardiac function and reduced cardiac abnormalities (27-29), although a recent study from Liang’s group, which was conducted on mice with type I diabetes, conflicted with this notion (26). Restoration of autophagic flux by Akt2 deletion and reactivation of autophagosome formation by Mif knockout also improved cardiac function in mice fed HFD (18,19). We found that rapamycin treatment restored autophagy and improved the myocardial tolerance to ischemia in mice with HFD-induced obesity and metabolic syndrome (13). The protective effects of rapamycin were lost in the presence of autophagy disruption. This evidence, coupled with recent results obtained in other organs where autophagy reactivation reduced diabetes-induced abnormalities (4-6), supports the idea that boosting autophagy may be a therapeutic intervention in patients with diabetes.

Several approaches might be suitable for activating cardiac autophagy in patients with metabolic abnormalities (Figure 1). As mentioned before, mTORC1 signaling is activated in the heart and vasculature of mice with obesity and diabetes (13,18,19,21,24,48,50,52). When it is hyperactivated, mTORC1 signaling is detrimental by inducing cardiac hypertrophy and cellular senescence and by reducing autophagy (53). mTORC1 inhibition was shown to reduce diabetic cardiomyopathy, HFD-induced increases in infarct size after both myocardial and cerebral ischemia, and endothelial cell senescence (13,50,52). This suggests that mTOR inhibitors might be appropriate for autophagy reactivation and treatment of diabetes-induced cardiovascular abnormalities. Rapamycin is the most studied mTOR inhibitor and there is a large amount of evidence in the literature indicating its beneficial effect against chronic maladaptive cardiac remodeling, hypertrophy and acute ischemia (53). However, rapamycin might not be an ideal drug for chronic treatment, particularly in patients with diabetes, since it can disrupt the mTORC2, which promotes cardiomyocyte survival, and would aggravate the insulin resistance status (54). A recent work from Sussman’s group demonstrated that selective mTORC1 inhibition by PRAS40 reduces diabetic cardiomyopathy and improves metabolic status and insulin sensitivity in mice with HFD-induced diabetes (50). This suggests that a selective mTORC1 inhibition by PRAS40, or potentially by Astrin, an mTORC1 inhibitor (55) or by Rheb inhibition (13), could be an appropriate way to treat cardiac abnormalities induced by metabolic derangements.

AMPK activators may also represent an alternative approach to reactivate autophagy in the diabetic heart. AMPK was found to be inhibited in the hearts of mice with both genetically and dietarily induced diabetes (13,18,19,21,26-29,48). AMPK is a positive regulator of
autophagy by inhibiting the mTORC1 pathway, by directly phosphorylating ULK1, or by modulating the Beclin-1-BCL-2 interaction (28,56). In mice with type I diabetes, reactivation of AMPK by metformin rescued cardiac autophagy and diabetes-induced cardiac anomalies. The beneficial effects of metformin on cardiomyocytes exposed to hyperglycemia were lost in the presence of autophagy disruption (28). Metformin is probably the best candidate to activate autophagy in the context of diabetes, particularly of type II diabetes, since metformin can also improve insulin sensitivity and lower glycemia at the same time. Interestingly, a recent study demonstrated that catalase overexpression rescues HFD-induced suppression of autophagy by reactivating AMPK (21). These results are supported by our previous work showing that ROS oxidize and inhibit AMPK, whereas thioredoxin-1 preserves AMPK activation by reducing it (57). Notably, physiological levels of ROS are critical for autophagy activation during physiological processes, and catalase was previously shown to inhibit autophagy (58). It is possible that exaggerated and pathological levels of ROS in the hearts of mice with obesity and diabetes exert a paradoxical effect on autophagy by inhibiting it.

AMPK was previously shown to regulate SIRT1 activity (55). SIRT1 activation is also another possible approach to rescue autophagy in the presence of metabolic abnormalities (24,29). SIRT1 was found to be inhibited in the heart by both type I and type II diabetes. We previously found that SIRT1 promotes autophagy by activating the FOXO1/RAB7 pathway (59). Resveratrol, a SIRT1 activator, was previously found to reactivate autophagic flux in mice with type I diabetes and to reduce cardiac dysfunction, oxidative stress, and cardiomyocyte apoptosis (29).

Statins may also be appropriate for reducing cholesterol and increasing autophagy at the same time. In fact, previous work demonstrated that statin treatment induces mitophagy, a cargo-specific form of autophagy that specifically degrades mitochondria (60), and reduces ischemic injury (61). In addition, atorvastatin was previously found to reactivate cardiac autophagy in a pig model of metabolic syndrome (62).

A recent study demonstrated that HFD-induced obesity and diabetes lead to a cellular accumulation of calcium in the cytosol of hepatocytes, thereby leading to an impairment of autophagosome-lysosome fusion (4). Interestingly, this defect could be rescued by the calcium-channel blocker verapamil, thereby suggesting that this drug may also be suitable for autophagy reactivation in metabolic syndrome.

Dioscin was recently found to be a strong reactivator of autophagy in the liver of obese mice, thereby reducing oxidative stress and lipotoxicity (5). Soluble epoxide hydrolase inhibitor was also found to promote autophagy and inhibit ER stress in the liver of fat-1 obese mice (63).

Treatment with carbon monoxide (CO)-releasing agents can also promote autophagy in the hearts of mice fed HFD and rescue cardiac function by improving mitochondrial function (32). In fact, at low doses, CO is known to
promote physiological effects and improve the metabolic status. In support of this evidence, overexpression of heme oxygenase-1, which promotes CO production, has recently been found to activate autophagy, inhibit apoptosis and oxidative stress, and rescue cardiac abnormalities and dysfunction in streptozotocin-induced diabetes (64).

Finally, physical exercise is an important therapeutic intervention to treat metabolic syndrome. A recent work from Levine’s group showed that exercise activates autophagy in the skeletal muscle of mice fed HFD by disrupting the Beclin-1-BCL-2 interaction. Exercise improved glucose tolerance in obese mice, and this effect was lost in mice with a defect in exercise-induced autophagy. This data suggests that physical exercise may be a valid option to improve the glucose tolerance of subjects with metabolic syndrome and to reactivate autophagy at the same time.

**Perspectives**

Numerous lines of evidence indicate that autophagy is inhibited in the presence of obesity, diabetes, and metabolic syndrome. Metabolic abnormalities appear to affect both autophagosome formation and autophagic flux. Future studies are required to understand how different metabolic abnormalities, such as obesity, hyperglycemia, and dyslipidemia impact the autophagic machinery and through which mechanisms. This would allow the development of specific strategies to reactivate autophagy in the presence of different combinations of metabolic abnormalities. Currently, the most promising therapeutic approach to rescue the autophagy suppression by metabolic abnormalities in the cardiovascular system is represented by mTORC1 inhibition. Metformin and statins are also quite appropriate because they can improve the metabolic status and increase autophagy at the same time. Ideally, molecules promoting autophagy by interfering specifically with the autophagic machinery would be the most appropriate agents to reactivate autophagy in the presence of metabolic abnormalities, so that they could be used in combination with the other antidiabetic and lipid-lowering drugs. In this regard, Levine’s group has recently developed a small peptide able to activate autophagy by interacting with the negative regulator of autophagy, GAPR-1 (65). Finally, future studies are encouraged to investigate how metabolic abnormalities specifically affect cargo-specific forms of autophagy, particularly mitophagy. The impact of metabolic derangements on mitochondrial fusion and fission also needs to be clarified since mitochondrial dynamics and autophagy affect each other, as we recently demonstrated (66).

**Acknowledgements**

The authors wish to thank Christopher D. Brady and Daniela Zablocki for critical reading of the manuscript and suggestions.

**Footnote**

Conflicts of Interest: The authors have no conflicts of interest to declare.

Financial Disclosure: This work was also supported by the Fondation Leducq Transatlantic Networks of Excellence. SS was supported by a Postdoctoral Fellowship from the Founders Affiliate, American Heart Association, and partially by a grant from the Italian Society of Cardiology and Italian Society of Hypertension, and is currently supported by a grant from the NJ Commission on Cancer Research.

**References**

8. Liu K, Zhao E, Ilyas G, et al. Impaired macrophage...


60. Sabe AA, Elmadhun NY, Sadek AA, et al. Differential effects of atorvastatin on autophagy in ischemic and nonischemic myocardium in Ossabaw swine with metabolic...